Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulvestrant +/- MK-0646 and Dasatinib in Metastatic Breast Cancer
NCT00903006Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2009
- Primary completion
- May 2013
- Modality
- Fragment-Derived Small Molecules, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib, dalotuzumab in breast cancer, sponsored by University of Texas MD Anderson Cancer Center. Started Nov 2009; status: terminated.
02
Drugs
dasatinibdalotuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00903006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00903006.